journal article·2018-10-31Open access

Using gold nanoparticles in diagnosis and treatment of melanoma cancer

Salman Bagheri, Maryam Yasemi, Elmira Safaie-Qamsari, Jamal Rashidiani, Morteza Abkar, Mahmoud Hassani, Seyed Ali Mirhosseini, Hamid Kooshki

Abstract

Several studies have been devoted to clear functionalization of gold nanoparticles (AuNPs) in different fields such as cellular and molecular biology, microbiology, immunology and physiology. In line with the high diagnostic value of AuNPs, its therapeutic application has been intensively developed in tumour therapy, in recent years. One of the best clinical applications of AuNPs is its use in targeted delivery of anti-cancer drugs. Recent studies have focused on the application of AuNPs to treat melanoma - a malignant neoplasm sourced from melanocytes skin cells - with poor prognosis in advanced stages. Furthermore, early diagnosis can be successfully achieved through utilizing this technique even at early stages with localized distribution. Herein, this study details the previous researches focusing on the use of AuNPs as a novel diagnostic and therapeutic option in management of melanoma.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Gold and Silver Nanoparticles Synthesis and Applications · Photoacoustic and Ultrasonic Imaging

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Nano Biotechnology Research Center, Baqiyatallah University of Medical Sciences

Immunology Research Center, Tabriz University of Medical Sciences

Department of Immunology, School of Medicine, Tabriz University of Medical Sciences

Department of Cell and Molecular Biology, Science and Research Branch, Islamic Azad University

Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences

Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences

Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences

References (100+)

Show source-provided references
1. 10.4103/0975-9476.8252310.4103/0975-9476.82523 ↗
2. 10.1007/s10787-007-0021-x10.1007/s10787-007-0021-x ↗
3. Anthony F. Panacea aurea: sive tractatus duo de ipsius auro potabili. Ex Bibliopolio Frobeniano.Hamburgi: ex Bibliopolio Frobeniano; 1618.
4. 10.1039/a904518j10.1039/a904518j ↗
5. 10.1128/CDLI.10.4.506-513.200310.1128/CDLI.10.4.506-513.2003 ↗
6. 10.3390/biomedicines503003810.3390/biomedicines5030038 ↗
7. 10.1016/j.ejmech.2017.06.03410.1016/j.ejmech.2017.06.034 ↗
8. 10.3390/molecules2205085710.3390/molecules22050857 ↗
9. 10.1039/C7CC00641A10.1039/C7CC00641A ↗
10. 10.2217/nnm.13.5810.2217/nnm.13.58 ↗
11. 10.1016/j.bios.2016.10.04510.1016/j.bios.2016.10.045 ↗
12. 10.4161/hv.2679610.4161/hv.26796 ↗
13. 10.1021/la204289k10.1021/la204289k ↗
14. 10.1039/C1CS15166E10.1039/C1CS15166E ↗
15. 10.1016/j.jconrel.2009.12.00610.1016/j.jconrel.2009.12.006 ↗
16. 10.2340/00015555-203510.2340/00015555-2035 ↗
17. 10.1007/s10103-017-2267-x10.1007/s10103-017-2267-x ↗
18. 10.1002/smll.20100013410.1002/smll.201000134 ↗
19. 10.2217/nnm.11.18910.2217/nnm.11.189 ↗
20. Biosciences IN. Pilot study of AuroLase (tm) therapy in refractory and/or recurrent tumors of the head and neck. ClinicalTrials gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000.
21. Biosciences N. Inc. Efficacy study of AuroLase therapy in subjects with primary and/or metastatic lung tumors. ClinicalTrials gov [Internet]. Bethesda (MD): National Library of Medicine; 2000.
22. 10.1371/journal.pone.017799710.1371/journal.pone.0177997 ↗
23. 10.1007/s10103-007-0470-x10.1007/s10103-007-0470-x ↗
24. 10.1021/nl900031y10.1021/nl900031y ↗
25. Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. AACR. 2013;73:2412?2417.
26. 10.1039/C5NR08463F10.1039/C5NR08463F ↗
27. 10.1073/pnas.090956510710.1073/pnas.0909565107 ↗
28. 10.1021/ja057254a10.1021/ja057254a ↗
29. 10.1021/jp409298f10.1021/jp409298f ↗
30. 10.1039/C4CP00902A10.1039/C4CP00902A ↗
31. 10.1021/acsami.5b0522510.1021/acsami.5b05225 ↗
32. 10.1002/wnan.12010.1002/wnan.120 ↗
33. 10.7150/thno.663010.7150/thno.6630 ↗
34. 10.1109/TUFFC.2014.298010.1109/TUFFC.2014.2980 ↗
35. 10.1007/s11051-010-9911-810.1007/s11051-010-9911-8 ↗
36. 10.1038/nnano.2012.20710.1038/nnano.2012.207 ↗
37. 10.1002/anie.20130946410.1002/anie.201309464 ↗
38. 10.1039/C1CS15233E10.1039/C1CS15233E ↗
39. 10.1016/j.phrs.2010.03.00510.1016/j.phrs.2010.03.005 ↗
40. 10.1039/C7NR02280H10.1039/C7NR02280H ↗
41. 10.1016/j.biomaterials.2014.04.00510.1016/j.biomaterials.2014.04.005 ↗
42. 10.1039/C7NR03096G10.1039/C7NR03096G ↗
43. 10.1016/j.ymeth.2014.02.00610.1016/j.ymeth.2014.02.006 ↗
44. 10.1016/j.jphotobiol.2015.08.02810.1016/j.jphotobiol.2015.08.028 ↗
45. 10.1016/j.talanta.2013.09.06210.1016/j.talanta.2013.09.062 ↗
46. 10.1021/nn901877h10.1021/nn901877h ↗
47. 10.1016/j.biomaterials.2011.01.00110.1016/j.biomaterials.2011.01.001 ↗
48. 10.1016/j.biomaterials.2011.10.05210.1016/j.biomaterials.2011.10.052 ↗
49. 10.1088/0957-4484/20/39/39510210.1088/0957-4484/20/39/395102 ↗
50. 10.1021/nn100736c10.1021/nn100736c ↗
51. 10.7150/thno.536910.7150/thno.5369 ↗
52. 10.1364/BOE.2.00254010.1364/BOE.2.002540 ↗
53. 10.1002/smll.20120177910.1002/smll.201201779 ↗
54. 10.1117/12.76412610.1117/12.764126 ↗
55. 10.1166/jbn.2010.110510.1166/jbn.2010.1105 ↗
56. 10.1364/OE.16.01860510.1364/OE.16.018605 ↗
57. 10.1021/nl802746w10.1021/nl802746w ↗
58. 10.1016/j.ejrad.2009.01.04510.1016/j.ejrad.2009.01.045 ↗
59. 10.2147/IJN.S12444210.2147/IJN.S124442 ↗
60. 10.1016/j.jphotobiol.2016.06.05510.1016/j.jphotobiol.2016.06.055 ↗
61. 10.1021/la402003b10.1021/la402003b ↗
62. 10.1016/j.bios.2012.02.01110.1016/j.bios.2012.02.011 ↗
63. 10.1002/anie.20150513310.1002/anie.201505133 ↗
64. 10.1016/j.msec.2016.03.03410.1016/j.msec.2016.03.034 ↗
65. 10.1016/j.jconrel.2016.03.00910.1016/j.jconrel.2016.03.009 ↗
66. 10.2174/156720181466617031611343210.2174/1567201814666170316113432 ↗
67. 10.2147/IJN.S11961810.2147/IJN.S119618 ↗
68. 10.1002/chem.20160243410.1002/chem.201602434 ↗
69. 10.1002/wnan.16110.1002/wnan.161 ↗
70. 10.21037/atm.2016.12.4610.21037/atm.2016.12.46 ↗
71. 10.1080/21691401.2017.130539310.1080/21691401.2017.1305393 ↗
72. 10.2217/nnm-2016-030610.2217/nnm-2016-0306 ↗
73. 10.1080/1547691X.2016.123452210.1080/1547691X.2016.1234522 ↗
74. 10.1016/B978-0-12-391858-1.00008-310.1016/B978-0-12-391858-1.00008-3 ↗
75. 10.1039/C2NR32338A10.1039/C2NR32338A ↗
76. 10.1016/j.molimm.2008.08.27710.1016/j.molimm.2008.08.277 ↗
77. 10.1073/pnas.110520010810.1073/pnas.1105200108 ↗
78. 10.1039/C0CS00018C10.1039/C0CS00018C ↗
79. 10.2217/nnm.11.7910.2217/nnm.11.79 ↗
80. 10.1021/mp800051m10.1021/mp800051m ↗
81. 10.1099/vir.0.066084-010.1099/vir.0.066084-0 ↗
82. 10.1007/s12088-017-0640-x10.1007/s12088-017-0640-x ↗
83. 10.1002/adma.20120044610.1002/adma.201200446 ↗
84. 10.1146/annurev-pathol-012513-10465810.1146/annurev-pathol-012513-104658 ↗
85. 10.1056/NEJMoa05009210.1056/NEJMoa050092 ↗
86. 10.1371/journal.pmed.005012010.1371/journal.pmed.0050120 ↗
87. Markovic SN Erickson LA Rao RD et al. editors. Malignant melanoma in the 21st century. Part 1: epidemiology risk factors screening prevention and diagnosis. Mayo Clin Proc. 2007;82:364–380.10.1016/S0025-6196(11)61033-1 ↗
88. Rastrelli M, Tropea S, Rossi CR, et al. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014;28:1005–1011.
89. Sandru A, Voinea S, Panaitescu E, et al. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014;7:572.
90. 10.3322/canjclin.54.3.13110.3322/canjclin.54.3.131 ↗
91. Sharif S, Haque AU, Ahmed A. Blue melanoma simulating blue nevus. Int. j. pathol. 2013;11:73–77.
92. 10.1080/14740338.2017.134330110.1080/14740338.2017.1343301 ↗
93. 10.1002/cncr.2489910.1002/cncr.24899 ↗
94. Gonzalez RJ, Kudchadkar R, Rao NG, et al. Adjuvant immunotherapy and radiation in the management of high-risk resected melanoma. Ochsner J. 2010;10:108–116.
95. 10.1016/j.soc.2010.09.00110.1016/j.soc.2010.09.001 ↗
96. 10.1200/JCO.2000.18.8.161410.1200/JCO.2000.18.8.1614 ↗
97. 10.1002/lsm.2106010.1002/lsm.21060 ↗
98. 10.2147/DDDT.S5841410.2147/DDDT.S58414 ↗
99. 10.1016/j.nano.2015.04.00110.1016/j.nano.2015.04.001 ↗
100. 10.1039/C5AN00446B10.1039/C5AN00446B ↗